Clinical Trial Update: Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating niraparib plus sintilimab in recurrent/metastatic nasopharyngeal carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Niraparib (Niraparib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: UNKNOWN